title: Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
abstract: OBJECTIVE
  The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine.
  
  
  METHODS
  The body mass index of male schizophrenic adolescent inpatients treated with olanzapine (N=10) and of 10 matched patients treated with haloperidol (N=10) were measured at baseline and after 4 weeks of treatment. For the patients treated with olanzapine, caloric intake, resting energy expenditure, and physical activity (determined through accelerometry and heart rate monitoring) were assessed at baseline and after 4 weeks of treatment.
  
  
  RESULTS
  Body mass index significantly increased in those treated with olanzapine but not in those given haloperidol. The increase in body mass index was due to an increase in caloric intake without change in diet composition. Olanzapine had no significant effect on resting energy expenditure. Daily energy expenditure was very low before and after treatment.
  
  
  CONCLUSIONS
  Olanzapine-induced weight gain is associated with a general increase in caloric intake.
authors.affiliation: Behavioral Genetic Clinic, Richard E. Feinberg Department of Psychiatry, Schneider Children's Medical Center of Israel, Petah Tiqwa. gothelf@post.tau.ac.il
authors.forename: Doron
authors.initials: D
authors.lastname: Gothelf
authors.forename: Bareket
authors.initials: B
authors.lastname: Falk
authors.forename: Pierre
authors.initials: P
authors.lastname: Singer
authors.forename: Michal
authors.initials: M
authors.lastname: Kairi
authors.forename: Moshe
authors.initials: M
authors.lastname: Phillip
authors.forename: Levana
authors.initials: L
authors.lastname: Zigel
authors.forename: Irit
authors.initials: I
authors.lastname: Poraz
authors.forename: Siegal
authors.initials: S
authors.lastname: Frishman
authors.forename: Naama
authors.initials: N
authors.lastname: Constantini
authors.forename: Gil
authors.initials: G
authors.lastname: Zalsman
authors.forename: Abraham
authors.initials: A
authors.lastname: Weizman
authors.forename: Alan
authors.initials: A
authors.lastname: Apter
mesh_terms: D000293:Adolescent; D000367:Age Factors; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015992:Body Mass Index; D004435:Eating / Q000187:drug effects*; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced*; D000077152:Olanzapine; D005082:Physical Exertion / Q000187:drug effects / Q000502:physiology; D010865:Pilot Projects; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D006220:Haloperidol; D000077152:Olanzapine